Publications

Search our bibliography using the filters on the right-hand side.

Displaying 101 through 132 of 132 publications.

Gnanasakthy A, Lewis SA, Clark MJ, Mordin MM, Evans E, DeMuro-Mercon CJ. The impact of primary endpoints on patient-reported outcome label claims. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 2012.

DeMuro C, Clark M, Coon C, Evans E, Mordin M, Gnanasakthy A. Assessment of PRO labels claims granted by the FDA as compared to the EMA. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 2012. Washington, DC. [abstract] Value Health. 2012 Jun; 15(4):A201. doi: 10.1016/j.jval.2012.03.1085

Brown TM, Siu K, Walker D, Pladevall-Vila M, Sander S, Mordin M. Development of a conceptual model of adherence to oral anticoagulants to reduce risk of stroke in patients with atrial fibrillation. J Manag Care Pharm. 2012 Jun 1;18(5):351-62.

Gnanasakthy A, Lewis S, Clark M, Evans E, Mordin M, DeMuro C. Reported outcomes as primary endpoints in confirmatory clinical trials. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 2012. Washington, DC. [abstract] Value Health. 2012 Jun; 15(4):A200.

DeMuro C, Clark M, Mordin M, Fehnel S, Copley-Merriman C, Gnanasakthy A. Reasons for rejection of patient-reported outcome label claims: a compilation based on a review of patient-reported outcome use among new molecular entities and niologic license applications, 2006-2010. Value Health. 2012 May 1;15(3):443-8.

Gnanasakthy A, Mordin M, Clark M, DeMuro C, Fehnel S, Copley-Merriman C. A review of patient-reported outcome labels in the United States: 2006 to 2010. Value Health. 2012 May;15(3):437-42. doi: 10.1016/j.jval.2011.11.032

Mordin M, Clark M, DeMuro C, Evans ED, Copley-Merriman K, Fehnel S, Gnanasakthy A. Pro label claims: an analysis based on a review of pros among new molecular entities and biologic license applications 2006-2010. Poster presented at the 2011 ISPOR 16th Annual International Meeting; June 3, 2011. [abstract] Value Health. 2011 May; 14(3):A29.

DeMuro C, Mordin M, Evans ED, Copley-Merriman K, Fehnel S, Gnanasakthy A. Reasons for rejection of PRO label claims: an analysis based on a review of PRO use among new molecular entities and biologic license applications 2006–2010. Poster presented at the 2011 ISPOR 16th Annual International Meeting; June 3, 2011. [abstract] Value Health. 2011 May; 14(3):A29.

Nelson LM, McLeod LD, Mordin MM, Farr J, Cole BJ, Uddin S, Engelhart L. Psychometric evaluation of the Knee Injury and Osteoarthritis Outcome Score (KOOS) subscales for patients with articular cartilage lesions of the knee using pilot study data of the Cartilage Autograft Implantation System (CAIS). Poster presented at the 9th World Congress of the International Cartilage Repair Society; September 2010.

Lewis SA, DeMuro-Mercon CJ, Mordin MM, Farr J, Cole BJ, Mithoefer K, Engelhart L. Measuring pain and function in patients with articular cartilage repair. Poster presented at the 9th World Congress of the International Cartilage Repair Society; September 2010.

Mordin MM, Lewis SA, Gnanasakthy A, DeMuro-Mercon CJ, Copley-Merriman K, Fehnel SE. Patient-reported outcomes in product development guidance. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 1, 2010. Atlanta, GA. [abstract] Value Health. 2010 May; 13(3):A-17-8.

Mordin M, Lewis SE, Gnanasakthy A, Demuro-Mercon C, Copley-Merriman K, Fehnel S. Patient-reported outcomes as mentioned in product development guidance. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 4, 2010. [abstract] Value Health. 2010 May; 13(3):A17-8.

Gnanasakthy A, DeMuro C, Mordin M, Copley-Merriman K, Mauskopf J. The role of the patient voice in health technology assessment. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 2010. Atlanta, GA. [abstract] Value Health. 2010 May; 13(3):A19. doi: 10.1016/S1098-3015(10)72074-X

Hollis KA, Mordin MM, Bechtel P, McLeod LD. Prospective observational studies: avoiding design pitfalls using process maps, decision-tree methods, and electronic medical records. Presented at the International Society for Pharmacoeconomics and Outcomes Research 15th Annual; May 2010.

Mordin MM, Clark M, Siersma CA, Copley-Merriman K, Gnanasakthy A. Impact of the FDA draft guidance on patient reported outcomes (PRO) label claims for approved drug products in the US: has it made a difference? Poster presented at the International Society for Pharmacoeconomics and Outcomes Research 14th Annual International Meeting; May 19, 2009. Orlando, FL. [abstract] Value Health. 2009 May; 12(3):A29.

Xu X, Mordin MM. Determine measurement properties of a pro instrument. Poster presented at the CBI's Premier Conference on Patient-Reported Outcomes (PRO); November 2007.

Hutchison RW, Anastassopoulos K, Vallow S, Mordin M, Olson W, Hewitt D, Sikirica V. Intravenous patient-controlled analgesia pump and reservoir logistics: results from a multicenter questionnaire. Hosp Pharm. 2007 Nov 1;42(11):1036-44.

Mordin M, Anastassopoulos K, van Breda A, Vallow S, Zhang M, Gargiulo K, Hewitt D, Olson W, Sikirica V. Clinical staff resource use with intravenous patient-controlled analgesia in acute postoperative pain management: results from a multicenter, prospective, observational study. J Perianesth Nurs. 2007 Aug 1;22(4):243-55.

Mordin MM. A new focus on performance and outcomes—the impact of mma part d on formulary decision making. Poster presented at the Institute for International Research (IIR) conference: Medicare Part D Congress; March 2006.

Hutchison R, Mordin MM, Albright Y, Zhang M, Vallow S. Hospital resources associated with intravenous patient-controlled analgesia in the management of acute pain following orthopedic or gynecologic surgery. Poster presented at the Midyear Clinical Meeting of the American Society of Health-System Pharmacists; December 2005.

Hamilton J, Mordin MM, Zhang M, Olson W, Hewitt D. Logistics of intravenous patient-controlled analgesia in the treatment of acute pain following orthopedic or gynecologic surgery. Poster presented at the Annual Meeting of the American Society of Anesthesiologists; October 2005.

Mordin MM. Practical applications of pharmacoeconomic and outcomes research in phase iv studies. Poster presented at the CBI's 6th Annual Phase IV Clinical Trials Conference: Design Research Programs to Meet Clinical, Regulatory and Marketing Objectives; September 2005. Philadelphia, PA.

Mordin MM, Gordon D, Anastassopoulos K, van Bretta A, Richardson D, Goss T. A multicenter, prospective, observational study of intravenous patient-controlled analgesia (IV-PCA) resource utilization (RU) in acute postoperative pain management. Poster presented at the Annual Meeting of the American Society of Health-System Pharmacists; June 2005.

Zhang M, Anastassopoulos K, Hutchison R, Olson W, Goss T, Hewitt D, Gargiulo K, Siccardi M, Mordin MM. Summary of hospital logistics associated with intravenous patient-controlled analgesia (IV-PCA) for acute postoperative pain management. Poster presented at the 2005 ISPOR 10th Annual International Meeting; May 2005. Washington, DC.

Schmidt RA, Ackerman SJ, Newstead GM, Quam JP, Mordin MM, Anastassopoulos K, Nishikawa RM. Comparative feature analysis of computed radiography for mammography (CRM) soft copy display vs. crm hard copy film: an observer performance study. Poster presented at the 90th Scientific Assembly and Annual Meeting of the Radiology Society of North America; November 2004.

Quam JP, Ackerman SJ, Mordin MM, Bassett LW. Conspicuity and characterization of findings on computed radiography for mammography vs. screen-film mammography: results from a prospective clinical trial. Poster presented at the 89th Scientific Assembly and Annual Meeting of the Radiology Society of North America; November 2003.

Ackerman SJ, Mordin M, Reblando J, Xu X, Schein J, Vallow S, Brennan M. Patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release among patients with chronic nonmalignant pain. J Manag Care Pharm. 2003 May 1;9(3):223-31.

Ellis CN, Mordin MM, Adler EY. Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol. 2003 Feb 1;4(2):131-9.

Duff SB, Mordin MM. Strategies for assessing health economic and quality-of-life outcomes in multiple sclerosis. Expert Rev Pharmacoecon Outcomes Res. 2002 Dec;2(6):577-87.

Menter A, Gottlieb A, Griffiths C, Mordin MM. Health-related quality of life impact of weekly intravenous or intramuscular alefacept in patients with psoriasis: results from two randomized, placebo-controlled phase III trials. Poster presented at the Annual Meeting of the American Academy of Dermatology; February 2002.

Buchner DA, Graboys TB, Johnson K, Mordin MM, Goodman L, Partsch DS, Goss TF. Development and validation of the ITG Health-Related Quality-of- Life Short-Form measure for use in patients with coronary artery disease. Integrated Therapeutics Group. Clin Cardiol. 2001 Aug;24(8):556-63.

McGrath M. Issues in designing, selecting, and interpreting a quality of life instrument. Poster presented at the Outcomes Research & Design Conference; March 2000.